Briefing
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
Six-year update of CLL14, including long-term PFS/OS and MRD outcomes after fixed-duration first-line venetoclax-obinutuzumab. Level 2.
- Design: paper
- Assay: Long-term MRD and survival after fixed-duration Ven-O